LSIPR 50 2018: Uniting the IP chorus
Brexit has created many uncertainties in the IP arena and the CEO of the UK Intellectual Property Office is urging stakeholders to speak up, so that the office isn’t the “lone voice” advocating the importance of IP.
LSIPR 50 2018: Levelling the medicines playing field
Speaking to LSIPR Leena Menghaney, regional head of Médecins Sans Frontières’ Access Campaign in South Asia, explains the importance of a balanced IP policy in fostering healthy generic competition.
Investing in patent search: tips for practitioners
In order to maximise the value from the patent search process, IP practitioners should take note of several tips including offering clear guidance to the searcher—and even saying ‘thank you’. Ellen Sherin of GQ Life Sciences reports.
The future of precision medicine part 1: challenges and opportunities
The healthcare industry and governments around the world are turning to precision medicine as an opportunity and a potential saviour. Daniel Lim of Kirkland & Ellis discusses the issues around translating the promise of precision medicine into real world clinical practice.
Conference preview: International Pharma Patent Term Extensions Forum
C5’s International Pharma Patent Term Extensions Forum, which will be held in Munich, Germany on June 19 and 20, will provide guidance on patent term extensions in the world’s key IP regions, as LSIPR finds out.
Protecting patients, and patents
Drug companies can take heart from a range of best practices in the battle against counterfeit medicines, as LSIPR finds out.
Medicines regulation after Brexit: compromise the key
With Brexit looming, questions are being asked about the future regulatory relationship between the EU and the UK, with life sciences companies wondering how they will be affected. LSIPR reports.
Regulation and licensing: the CRISPR conundrum continues
As innovation in the CRISPR field continues across the world, questions are being asked about the role of regulating such a powerful tool, while discussions around licensing the technology continue, as LSIPR reports.
ZFN: a rival to CRISPR
As a rival to CRISPR in the gene-editing field, zinc finger nuclease technology is making a name for itself. LSIPR hears from Sandy Macrae, CEO of Sangamo Therapeutics, one of the key players in this area.
Keeping quiet on clinical trials
Pharma companies with an interest in protecting clinical trial data in Mexico should follow international developments rather than looking closer to home, say Anna Arroyo and Fernando Granados of Uhthoff Gómez Vega & Uhthoff.
